Hims & Hers Health Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Andrew Dudum
Chief executive officer
US$14.4m
Total compensation
| CEO salary percentage | 4.2% |
| CEO tenure | 8yrs |
| CEO ownership | 8.6% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Jan 29Hims & Hers Health: The Market Is Likely Wrong
Jan 19Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Jan 09Hims & Hers: Ready For Liftoff In 2025
Jan 02Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted
Dec 19Hims & Hers: Look At What Matters Most
Dec 12Hims & Hers: The Show Must Go On
Dec 05Hims & Hers: Driving Growth In Wellness
Nov 29Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge
Nov 26
Hims & Hers Health: The Amazon Curse Is Being Overstated
Nov 15Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$101m |
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$14m | US$612k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$11m | US$600k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$15m | US$574k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$72m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$27m | US$527k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$25m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$254k | US$254k | -US$72m |
Compensation vs Market: Andrew's total compensation ($USD14.40M) is above average for companies of similar size in the US market ($USD7.89M).
Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.
CEO
Andrew Dudum (35 yo)
8yrs
Tenure
US$14,401,411
Compensation
Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8yrs | US$14.40m | 8.55% $ 595.3m | |
| Chief Financial Officer | 3yrs | US$7.43m | 0.054% $ 3.8m | |
| Chief Operating Officer | 4yrs | US$6.77m | 0.32% $ 22.5m | |
| Chief Legal Officer & Corporate Secretary | 4yrs | US$5.21m | 0.076% $ 5.3m | |
| Chief Medical Officer | 2.1yrs | US$198.26k | 0.091% $ 6.4m | |
| Chief Commercial Officer | less than a year | US$6.71m | 0.089% $ 6.2m | |
| Senior VP | 5.6yrs | US$961.12k | 0.0034% $ 233.2k | |
| Chief Communications Officer | 1.3yrs | no data | no data | |
| Senior Vice President of Human Resources | 2.8yrs | no data | no data | |
| Senior VP & Member of Medical Advisory Board | no data | no data | no data | |
| Chief Pharmacy & Innovation Officer | 2.1yrs | no data | no data | |
| Senior Vice President of Mental Health | 1.8yrs | no data | no data |
2.8yrs
Average Tenure
44yo
Average Age
Experienced Management: HIMS's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4yrs | US$14.40m | 8.55% $ 595.3m | |
| Chief Medical Officer | 2.9yrs | US$198.26k | 0.091% $ 6.4m | |
| Senior VP & Member of Medical Advisory Board | 3yrs | no data | no data | |
| Independent Director | 4.3yrs | US$194.26k | 0.025% $ 1.7m | |
| Lead Independent Director | 4.3yrs | US$227.41k | 0.076% $ 5.3m | |
| Independent Director | 3.8yrs | US$205.51k | 0.033% $ 2.3m | |
| Member of Medical Advisory Board | 3.1yrs | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 3.1yrs | no data | no data | |
| Member of Medical Advisory Board | 3.1yrs | no data | no data | |
| Member of Medical Advisory Board | 3.1yrs | no data | no data | |
| Member of Medical Advisory Board | 3.1yrs | no data | no data |
3.1yrs
Average Tenure
53yo
Average Age
Experienced Board: HIMS's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 22:39 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hims & Hers Health, Inc. is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Allen Lutz | BofA Global Research |
| Michael Cherny | BofA Global Research |